Senti Bio to Present at the MedInvest Biotech & Pharma Conference
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, will participate in the upcoming MedInvest Biotech & Pharma Conference in Palo Alto, California.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, will participate in the upcoming MedInvest Biotech & Pharma Conference in Palo Alto, California.
Dr. Kanya Rajangam, President, Head of Research & Development and Chief Medical Officer, will deliver a presentation on Wednesday, September 24, 2025, at 9:55 AM PT. The management team will also be available for one-on-one meetings with qualified investors attending the conference.
A live webcast of the presentation will be accessible through the Events page in the Investors section of sentibio.com.
Details
News Market Reaction – SNTI
On Sep 18, the day this news came out, SNTI closed 1.46% above the previous close.
Data tracked by StockTitan Argus for the Sep 18 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live webcast presentation on Wednesday, September 24th at 9:55 AM PT
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, will present on Wednesday, September 24, 2025 at 9:55 AM PT at the MedInvest Biotech & Pharma Conference being held in Palo Alto, California.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (sentibio.com)
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.